Labrie, Marilyne http://orcid.org/0000-0003-3957-5533
Li, Allen http://orcid.org/0000-0001-7482-8204
Creason, Allison http://orcid.org/0000-0001-5724-1276
Betts, Courtney
Keck, Jamie
Johnson, Brett http://orcid.org/0000-0001-6810-551X
Sivagnanam, Shamilene http://orcid.org/0000-0001-5966-1522
Boniface, Christopher http://orcid.org/0000-0003-0130-7517
Ma, Hongli
Blucher, Aurora
Chang, Young Hwan http://orcid.org/0000-0001-8764-1959
Chin, Koei http://orcid.org/0000-0001-8061-7462
Vuky, Jacqueline
Guimaraes, Alexander R.
Downey, Molly http://orcid.org/0000-0001-5212-2286
Lim, Jeong Youn
Gao, Lina
Siex, Kiara
Parmar, Swapnil
Kolodzie, Annette http://orcid.org/0000-0002-9606-6500
Spellman, Paul T.
Goecks, Jeremy http://orcid.org/0000-0002-4583-5226
Coussens, Lisa M. http://orcid.org/0000-0003-2389-1865
Corless, Christopher L.
Bergan, Raymond http://orcid.org/0000-0001-8690-4876
Gray, Joe W. http://orcid.org/0000-0001-9225-6756
Mills, Gordon B.
Mitri, Zahi I. http://orcid.org/0000-0001-8765-7723
Article History
Received: 8 October 2020
Accepted: 22 September 2021
First Online: 19 October 2021
Competing interests
: G.B.M.: Consultant/Scientific Advisory Board (AstraZeneca, Chrysalis, ImmunoMET, Ionis, Lilly USA, LLC, PDX Pharma, Signalchem Lifesciences, Symphogen, Tarveda); Stock/Options/Financial Companies (Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindletop Ventures, Tarveda); Licensed Technology Companies (HRD assay to Myriad Genetics, DSP to Nanostring). C.L.C.: Consultant/Scientific Advisory Board (Amgen, Cepheid/Daneher); Stock/Options (Guardant Health). R.B.: inventor on patents related to KBU2046 and therapeutically targeting cancer motility, and co-owner of Third Coast Therapeutics, which has an option to license those patents; <b>JV</b>: Consultant/Scientific Advisory Board (Seattle Genetics/Astellas), research funding (Celldex, Innocrin Pharma, Roche/Genentech, Novartis, Merck, Fortis Therapeutics). L.M.C.: paid consultant for Cell Signaling Technologies, received reagent and/or research support from Plexxikon Inc., Pharmacyclics, Inc., Acerta Pharma, LLC, Deciphera Pharmaceuticals, LLC, Genentech, Inc., Roche Glycart AG, Syndax Pharmaceuticals Inc., and NanoString Technologies, and is a member of the Scientific Advisory Boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, Inc, Verseau Therapeutics, Kineta, Inc., and Cytomix Therapeutics, Inc. A.R.G.: Siemens Speaker’s Bureau, Consultant for Takeda Pharmaceuticals, Inc., Expert Witness for Rice, Dolan & Kershaw and Witherspoon & Kelley. P.T.S.: IP licensed to Cepheid, equity in convergent genomics, consulting for Foundation Medicine. J.G.W.: Business Relationships (Abbott Diagnostics, Danaher (formerly Cepheid), PDX Pharmaceuticals and Thermo Fisher Scientific (formerly FEI), Zeiss, Micron), Company Ownership Positions (Convergent Genomics, KromaTid, PDX Pharmaceuticals), Full- or Part-time Employment or Service as an Officer, Board Member or Other Position of Leadership (Oregon Health & Science University; Cooperative Japan-United States Radiation Effects Research Foundation), Consulting or Advisory Relationships (APOBEC Cancer Program, University of Minnesota; Comprehensive Cancer Center, University of New Mexico (UNM); MJ Murdock Charitable Trust; New Leaf Ventures; Susan G. Komen® for the Cure, University of Denver Medical Center), Stock Ownership (Abbott Diagnostics, AbbVie, Alphabet, Amgen, Amazon, Apple Corporation, Berkshire Hathaway, Cameco, Chevron, ConocoPhillips, Cisco Systems, Clorox, Colgate-Palmolive, Crown Castle, Devon Energy, Disney, Exxon Mobile, General Electric, Gilead, Intel, Nasdaq, Nvidia, PepsiCo, Philips, Procter & Gamble, Swiss Helveita, Walt Disney, Wells Fargo, and Zimmer Biomet). The remaining authors declare no competing interests.